Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New liver study tests drug safety in patients with mild to moderate impairment

NCT ID NCT07550634

First seen May 03, 2026 · Last updated May 23, 2026 · Updated 5 times

Summary

This early-stage study looks at how a single dose of the drug MDR-001 is handled by the body in people with mild or moderate liver impairment compared to healthy volunteers. About 32 participants will take one tablet, and researchers will measure drug levels in the blood and monitor for side effects. The goal is to understand if liver function affects the drug's safety and processing, which helps guide future dosing recommendations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (MILD AND MODERATE, CHILD-PUGH CLASS A AND B) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.